Bayer to acquire AskBio for up to $4 billion

Tuesday 27 October 2020


Bayer AG is to pay up to $4 billion to acquire Asklepios BioPharmaceutical Inc (AskBio), a US gene therapy company with a clinical-stage pipeline and a significant manufacturing capacity. It will pay $2 billion upfront for the company and up to $2 billion in success-based milestones, of which three quarters are expected to be due over the next five years.